Pfizer Expands AI Collaboration with Saama to Accelerate Clinical Research


Saama, a provider of AI-based solutions for clinical development and commercialization, has announced an expanded partnership with global biopharmaceutical leader Pfizer. The multi-year agreement aims to accelerate clinical research and streamline data review processes using artificial intelligence (AI).

The collaboration between Saama and Pfizer began in 2020 when they partnered to automate Pfizer’s data review processes with AI. The result of this initial collaboration was Smart Data Quality (SDQ), which significantly reduced the time to lock the database. Under the new agreement, Pfizer will continue to scale SDQ to streamline and accelerate data review processes across its global studies.

The success of their initial collaboration during the development of Pfizer’s COVID-19 vaccine demonstrated the power of AI-enabled technology to improve and expedite the clinical trial process. Lisa Moneymaker, Chief Technology Officer and Chief Product Officer at Saama, believes that scaling across Pfizer’s broader portfolio will fundamentally change the way drug development is done, benefiting more people worldwide.

Demetris Zambas, Vice President and Global Head Data Monitoring and Management at Pfizer, emphasizes the importance of building a sustainable framework to accelerate analysis and reporting for clinical trials. The expanded partnership with Saama will leverage their cutting-edge AI-based technologies to reduce the time and effort required for data review and reconciliation, while improving data quality and consistency across routine and complex clinical studies.

The expanded agreement between Saama and Pfizer is not limited to SDQ. It also includes the adoption of Saama’s advanced Biometrics Research and Analysis Information Network, which aims to expedite regulatory submissions across Pfizer’s portfolio. This next-generation solution will streamline statistical programming and biostatistics workflows, digitize study specifications, and generate submission-ready tables, listings, and figures (TLF) artifacts. Furthermore, it sets the stage for future automation and innovation in accelerating trial submissions.

See also  Moto Star Jayo Archer's Tragic Death Sparks AI Debate in Hollywood

Saama’s AI-based solutions use advanced technology to manage the high volume and variety of clinical trial data. By centralizing and standardizing data from multiple sources, these solutions enable streamlined medical review processes, improve patient safety oversight, predict participant behavior, and expedite clinical signal discovery, among other benefits.

The Saama platform, consisting of AI-enabled software-as-a-service (SaaS) products and solutions, supports the full spectrum of clinical development. To learn more about Saama and its customized solutions and services, or to schedule a personalized demonstration, visit their website.

Saama will also be present at booth 813 at the SCOPE Summit from February 11-14 in Orlando, Florida. This event presents an opportunity for industry professionals to connect and exchange ideas about clinical trial solutions and innovations.

About Saama:
Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the development of the world’s first COVID-19 vaccine. Headquartered in Campbell, California, Saama has a global presence and is dedicated to helping customers save and improve lives.

Source: Business Wire

Frequently Asked Questions (FAQs) Related to the Above News

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Advait Gupta
Advait Gupta
Advait is our expert writer and manager for the Artificial Intelligence category. His passion for AI research and its advancements drives him to deliver in-depth articles that explore the frontiers of this rapidly evolving field. Advait's articles delve into the latest breakthroughs, trends, and ethical considerations, keeping readers at the forefront of AI knowledge.

Share post:



More like this

Global Edge Data Centers Market to Reach $46.4 Billion by 2030

Global edge data centers market set to hit $46.4 billion by 2030. Asia-Pacific leads growth with focus on IoT, cloud, and real-time analytics.

Baidu Inc Faces Profit Decline, Boosts Revenue with AI Advertising Sales

Baidu Inc faces profit decline but boosts revenue with AI advertising sales. Find out more about the company's challenges and successes here.

Alexander & Baldwin Holdings Tops FFO Estimates, What’s Next for the REIT?

Alexander & Baldwin Holdings surpasses FFO estimates, investors await future outlook in the REIT industry. Watch for potential growth.

Salesforce Stock Dips Despite New Dividend & Buyback

Despite introducing a new dividend & buyback, Salesforce's stock dipped after strong quarterly results. Investors cautious about future guidance.